This analysis of the UK biotech industry is the result of a joint collaboration between the BIA and Evaluate to examine the performance of the UK biotech industry over the past decade. The report provides a detailed view of the industry between 2005 and 2014 and highlights trends in M&A, drug approvals, venture financing and IPOs.

Over the past 10 years, the UK's biotech sector has outperformed other European countries, raising an impressive £923.7 million via IPOs and $2.4 billion in venture capital. The rise in optimism has been most evident in 2014 with the momentum continuing into 2015. 2014 was a big turning point for the UK biotech sector. In this year alone, on the public market, nine companies listed, raising a total of $408 million, almost half of the total IPO haul for the past decade.
 

Key highlights in UK Biotech: A 10 Year Horizon include:

• Strong confidence in UK market is reflected in recent IPO activity reaching $408 million in 2013, with a further two IPOs in 2015
• Good stock performance of new entrants, including 247% share gain by 4D Pharma since its IPO, helping to highlight the benefits of investing in the sector
• Increasing in exits (via IPO and trade sales) have created a 10 year in venture funding: investment in 2014 is up 71% to $430 million (2013: $251 million)
• Fewer larger financing deals took place in 2014, indicating a change in investment style
• Venture capital seed funding declined dramatically to 1 in 2014; although the $20 million raised equaled almost the total of the last four years combined
• UK is holding its own against the US and outperforming Europe in the past five years for venture funding

Please confirm your details on the form to download your complimentary copy of this report.